SG11201900561XA - Chemokine receptor modulators and uses thereof - Google Patents

Chemokine receptor modulators and uses thereof

Info

Publication number
SG11201900561XA
SG11201900561XA SG11201900561XA SG11201900561XA SG11201900561XA SG 11201900561X A SG11201900561X A SG 11201900561XA SG 11201900561X A SG11201900561X A SG 11201900561XA SG 11201900561X A SG11201900561X A SG 11201900561XA SG 11201900561X A SG11201900561X A SG 11201900561XA
Authority
SG
Singapore
Prior art keywords
avenue
international
apt
san
way
Prior art date
Application number
SG11201900561XA
Inventor
Hilary Beck
Berenger Biannic
Minna Hue Bui
Dennis Hu
John Ketcham
Jay Powers
Maureen Reilly
Omar Robles-Resendiz
Hunter Shunatona
James Walker
David Wustrow
Ashkaan Younai
Mikhail Zibinsky
Jeffrey James Jackson
Original Assignee
Flx Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flx Bio Inc filed Critical Flx Bio Inc
Publication of SG11201900561XA publication Critical patent/SG11201900561XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) W I P0 I P C T omit 01110011010II 111110lII ow (10) International Publication Number WO 2018/022992 Al (51) International Patent Classification: A61K 31/5377 (2006.01) C07D 401/12 (2006.01) (21) International Application Number: PCT/US2017/044369 (22) International Filing Date: 28 July 2017 (28.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/368,848 29 July 2016 (29.07.2016) US 62/426,087 23 November 2016 (23.11.2016) US (71) Applicant: FLX BIO, INC. [US/US]; 561 Eccles Avenue, South San Francisco, CA 94080 (US). (72) Inventors: BECK, Hilary, Plake; 115 Springdale Way, Emerald Hills, CA 94062 (US). BIANNIC, Berenger; 1600 E 3rd Avenue, Apt 2508, San Mateo, CA 94401 (US). BUI, Minna Hue, Thanh; 2445 25th Avenue, Oakland, CA 94601 (US). HU, Dennis, X.; 3014 Los Prados, Apt. 103, San Mateo, CA 94403 (US). KETCHAM, John, Michael; 817 N. Humboldt Street, Apt. 211, San Mateo, CA 94401 (US). POWERS, Jay, Patrick; 745 Rockaway Beach Avenue, Pacifica, CA 94044 (US). REILLY, Mau- reen, Kay; 85 Richland Avenue, Unit 5, San Francisco, CA 94110 (US). ROBLES-RESENDIZ, Omar; 1 Avocet Drive, Apt. 206, Redwood City, CA 94065 (US). SHUNA- TONA, Hunter, Paul; 79 Melrose Avenue, San Francisco, CA 94131 (US). WALKER, James, Ross; 9326 Ancient Oak Lane, Verona, WI 53593 (US). WUSTROW, David, Juergen; 116 Vallecitos Way, Los Gatos, CA 95032 (US). YOUNAI, Ashkaan; 397 Imperial Way, Apt. 143, Daly City, CA 94015 (US). ZIBINSKY, Mikhail; 1582 Hudson Street, Redwood City, CA 94061 (US). (74) Agent: YVON, Brigitte, L. et al.; Mintz Levin Cohn Fer- ris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 1-1 O \" (57) : Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity. (54) Title: CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF C
SG11201900561XA 2016-07-29 2017-07-28 Chemokine receptor modulators and uses thereof SG11201900561XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662368848P 2016-07-29 2016-07-29
US201662426087P 2016-11-23 2016-11-23
PCT/US2017/044369 WO2018022992A1 (en) 2016-07-29 2017-07-28 Chemokine receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
SG11201900561XA true SG11201900561XA (en) 2019-02-27

Family

ID=61016874

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900561XA SG11201900561XA (en) 2016-07-29 2017-07-28 Chemokine receptor modulators and uses thereof

Country Status (21)

Country Link
US (3) US10179787B2 (en)
EP (1) EP3490565B1 (en)
JP (1) JP6985388B2 (en)
KR (1) KR102566924B1 (en)
CN (1) CN109789146B (en)
AU (1) AU2017302635B2 (en)
BR (1) BR112019001732A2 (en)
CA (1) CA3032133A1 (en)
DK (1) DK3490565T3 (en)
ES (1) ES2925564T3 (en)
HU (1) HUE059242T2 (en)
IL (1) IL264397B2 (en)
MX (1) MX2019001223A (en)
NZ (1) NZ750182A (en)
PL (1) PL3490565T3 (en)
PT (1) PT3490565T (en)
RU (1) RU2768827C2 (en)
SG (1) SG11201900561XA (en)
TW (1) TWI817929B (en)
WO (1) WO2018022992A1 (en)
ZA (1) ZA201900961B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141864B2 (en) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Substituted anilines as CCR (4) antagonists
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
KR20180058741A (en) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them
EP3490565B1 (en) 2016-07-29 2022-06-08 RAPT Therapeutics, Inc. Azetidine derivatives as chemokine receptor modulators and uses thereof
RU2020118594A (en) * 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. ANTI-CANCER AGENTS
WO2019147862A1 (en) * 2018-01-26 2019-08-01 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
US20210002641A1 (en) * 2018-03-16 2021-01-07 The Regents Of The University Of Michigan Compositions and methods for treating graves disease
CN112292374B (en) * 2018-05-31 2023-01-03 信达生物制药(苏州)有限公司 Novel phosphoinositide 3-kinase inhibitor and preparation method and application thereof
KR102584855B1 (en) * 2018-06-26 2023-10-05 케이피씨 파마슈티컬스 인코포레이티드 Benzimidazole derivatives and their use as IDH1 inhibitors
US11446289B2 (en) * 2018-08-29 2022-09-20 Chemocentryx, Inc. Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
CN109796457B (en) * 2019-03-28 2020-03-06 苏州国匡医药科技有限公司 Preparation method and application of 2- (3- (azetidin-3-yl) piperidin-1-yl) ethyl-1-ol
CN112062728A (en) * 2019-05-25 2020-12-11 上海鑫凯化学科技有限公司 Synthetic method of 3, 5-dichloro-6-ethylpyrazine formamide
CN114728972A (en) * 2019-11-13 2022-07-08 拉普特医疗公司 Crystalline forms of a C-C chemokine receptor type 4 antagonist and uses thereof
AU2020401101A1 (en) * 2019-12-09 2022-06-30 Imago Biosciences, Inc. Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms
CN111471025A (en) * 2020-03-26 2020-07-31 兰州康寓信生物科技有限公司 Favipiravir intermediate and synthesis method of favipiravir
CN111732572B (en) * 2020-07-31 2020-11-13 苏州国匡医药科技有限公司 Preparation method of chiral antitumor drug FLX475 and intermediate thereof
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023196432A1 (en) * 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (en) 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
DK0495421T3 (en) 1991-01-15 1996-12-09 Alcon Lab Inc Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
JP2003535078A (en) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ Indole derivatives with vascular damage activity
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
AU2002354476A1 (en) * 2001-12-14 2003-06-30 Japan Tobacco Inc. Pyrazolopyridine derivatives and medicinal use thereof
WO2004007472A1 (en) * 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
WO2005082865A1 (en) * 2004-02-27 2005-09-09 Astellas Pharma Inc. Fused bicyclic pyrimidine derivative
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
NL2000323C2 (en) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine derivatives.
WO2007111227A1 (en) * 2006-03-24 2007-10-04 Astellas Pharma Inc. Acylaminopiperidine compound
JP2010208945A (en) * 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp Heterocyclic compound
KR101048448B1 (en) * 2008-11-21 2011-07-11 한국화학연구원 Novel pyrazolo [4,3-ｂ] pyridine derivatives or pharmaceutically acceptable salts thereof, preparation methods thereof and pharmaceutical compositions containing the same as active ingredients
JP2010126496A (en) * 2008-11-28 2010-06-10 Mitsubishi Tanabe Pharma Corp Heterocyclic compound
JP5520969B2 (en) 2009-02-26 2014-06-11 グラクソ グループ リミテッド Pyrazole derivatives for use as CCR4 receptor antagonists
WO2011048082A1 (en) * 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
CN102939283B (en) * 2010-04-22 2015-06-03 詹森药业有限公司 Indazole compounds useful as ketohexokinase inhibitors
US9040545B2 (en) * 2010-08-20 2015-05-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
JP6141864B2 (en) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Substituted anilines as CCR (4) antagonists
CN103974950B (en) * 2011-12-01 2016-12-21 凯莫森特里克斯股份有限公司 Substituted benzimidazole and benzopyrazoles class as CCR (4) antagonist
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2016021742A1 (en) * 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016192083A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3490565B1 (en) 2016-07-29 2022-06-08 RAPT Therapeutics, Inc. Azetidine derivatives as chemokine receptor modulators and uses thereof

Also Published As

Publication number Publication date
CA3032133A1 (en) 2018-02-01
PT3490565T (en) 2022-09-06
EP3490565A4 (en) 2019-12-25
TWI817929B (en) 2023-10-11
KR20190041471A (en) 2019-04-22
NZ750182A (en) 2023-03-31
WO2018022992A1 (en) 2018-02-01
DK3490565T3 (en) 2022-07-11
US10179787B2 (en) 2019-01-15
AU2017302635A1 (en) 2019-02-14
JP6985388B2 (en) 2021-12-22
EP3490565B1 (en) 2022-06-08
RU2019105534A (en) 2020-08-28
US20200239480A1 (en) 2020-07-30
HUE059242T2 (en) 2022-11-28
US20190152978A1 (en) 2019-05-23
RU2019105534A3 (en) 2020-10-20
CN109789146A (en) 2019-05-21
IL264397B2 (en) 2024-04-01
US10604526B2 (en) 2020-03-31
TW201808958A (en) 2018-03-16
BR112019001732A2 (en) 2019-05-07
AU2017302635B2 (en) 2021-09-16
RU2768827C2 (en) 2022-03-24
PL3490565T3 (en) 2022-09-26
IL264397B1 (en) 2023-12-01
EP3490565A1 (en) 2019-06-05
IL264397A (en) 2019-02-28
CN109789146B (en) 2023-04-18
MX2019001223A (en) 2019-11-11
ES2925564T3 (en) 2022-10-18
JP2019525962A (en) 2019-09-12
ZA201900961B (en) 2020-05-27
KR102566924B1 (en) 2023-08-11
US20180072740A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
SG11201900561XA (en) Chemokine receptor modulators and uses thereof
SG11201805136TA (en) Group b adenovirus encoding an anti-tcr-complex antibody or fragment
SG11201805506YA (en) Modulators of 5'-nucleotidase, ecto and the use thereof
SG11201809041TA (en) Compositions and methods for selective protein expression
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201804694SA (en) Dual controls for therapeutic cell activation or elimination
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201805784PA (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201808821WA (en) Agonistic antibodies that bind human cd40 and uses thereof
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201908492PA (en) Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201810465RA (en) Compositions and methods related to engineered fc constructs
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201806453TA (en) Improved blood-brain barrier endothelial cells derived from pluripotent stem cells for blood-brain barrier models